HealthCare Global Enterprises Shareholders Approve Board Changes and New Articles of Association
Healthcare Global Enterprises Limited (HCG) shareholders approved several key resolutions via postal ballot. Changes include appointing Dr. B.S. Ajaikumar as Non-Executive Director and Chairman, adding new Non-Executive and Executive Directors, and appointing an Independent Director. Shareholders also approved amended Articles of Association and consultancy agreements with Dr. Ajaikumar and Mrs. Rossi. The voting saw strong participation, with most resolutions receiving over 90% approval and representing 84.93% of the company's total paid-up equity capital.
01Jul 25
Karnataka Government Calls for Probe into Alleged Unfair Clinical Trials at HCG Bengaluru
The Karnataka government has requested the Drug Controller General of India (DCGI) to investigate alleged unfair clinical trials at Healthcare Global Enterprises Ltd's (HCG) Bengaluru facility. The inquiry was prompted by concerns raised by a former chairperson of HCG's Institutional Ethics Committee regarding patient safety, regulatory compliance, and institutional integrity in clinical trials. This development could have significant implications for HCG, a prominent cancer care provider, potentially affecting its reputation and regulatory standing.
10Jun 25
Healthcare Global Enterprises Unveils Ambitious Expansion Plan
Healthcare Global Enterprises (HCG) plans to add 1,000 beds over the next three years through a hybrid expansion model. The company aims to maintain a 20% EBITDA margin despite expansion. HCG reported 18% year-on-year revenue growth but a 65% decline in Profit After Tax. The company projects 15% overall revenue growth over the next three years.
09Jun 25
Healthcare Global Targets 19-20% Profit Margins in Efficiency Drive
Healthcare Global Enterprises Ltd, a major player in the Indian healthcare sector, has announced a strategic goal to maintain profit margins between 19% and 20%. This target demonstrates the company's commitment to financial stability and operational efficiency in the face of industry challenges. The focus on sustaining these margins suggests potential initiatives in cost management, resource optimization, and service delivery improvements. This financial objective provides a clear benchmark for stakeholders and reflects the company's confidence in its business model.
26May 25
Healthcare Global Enterprises Ltd Reports Mixed Q4 Financial Results
Healthcare Global Enterprises Ltd announced Q4 results with mixed performance. Consolidated revenue increased 18.26% year-over-year to ₹5.83 billion. However, net profit declined 71.37% to ₹67 million compared to the same quarter last year. Sequential growth showed 4.67% increase in revenue but 12.99% decrease in profit from the previous quarter.
02May 25
CCI Greenlights KKR's Share Acquisition in Healthcare Global Enterprises
The Competition Commission of India (CCI) has approved a proposed share acquisition in Healthcare Global Enterprises Limited by KKR, through its entities Hector Asia Holdings and KIA EBT II Scheme. This approval allows KKR, a global investment firm, to proceed with its investment in the prominent Indian healthcare company. While specific details of the acquisition remain undisclosed, this development could potentially reshape Healthcare Global Enterprises' future operations and strategic direction.
01May 25
CCI Greenlights KKR's Acquisition of Healthcare Global Enterprises
The Competition Commission of India (CCI) has approved KKR's proposed acquisition of Healthcare Global Enterprises Limited, a specialist in oncology care. The purchase will be executed through KKR's entities Hector Asia Holdings and KIA EBT II Scheme. This approval is a crucial step in KKR's expansion strategy in the Indian healthcare market, subject to additional regulatory approvals and closing conditions. While financial details are undisclosed, the acquisition could bring global expertise and capital to Healthcare Global Enterprises, potentially impacting India's healthcare industry landscape.
24Feb 25
KKR to Acquire Controlling Stake in HealthCare Global Enterprises for ₹3,428 Crore
Global investment firm KKR is set to acquire a controlling stake of up to 54% in HealthCare Global Enterprises Ltd (HCG), India's largest cancer care provider, for ₹3,428 crore ($400 million). The deal involves a two-tranche acquisition at ₹445 per share, with an open offer to public shareholders at ₹504.41 per share. HCG's founder, Dr. BS Ajaikumar, will transition to Non-Executive Chairman. The transaction, expected to close by Q3 2025, is subject to regulatory approvals and aims to support the development of medical infrastructure and oncology services in India.